Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

Taku Fujimura; Yumi Kambayashi; Yota Sato; Kayo Tanita; Sadanori Furudate; Akira Tsukada; Hisayuki Tono; Akira Hashimoto; Setsuya Aiba

doi:10.1159/000485612

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Tanita, Sadanori Furudate, Akira Tsukada, Hisayuki Tono, Akira Hashimoto, Setsuya Aiba

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Simultaneous or sequential, planned administration of ipilimumab could significantly enhance the antitumor effects of nivolumab in advanced melanoma patients. On the other hand, the efficacy of ipilimumab for nivolumab-resistant advanced melanoma is extremely poor. Therefore, additional supportive therapy for anti-PD-1 antibody therapy-resistant advanced melanoma has been widely investigated. In this report, we describe a case of multiple in-transit melanomas developing in a nivolumab-resistant patient successfully treated with ipilimumab in combination with imiquimod. Our present case suggested a possible therapy for nivolumab-resistant multiple in-transit melanomas using ipilimumab in combination with topical imiquimod.

Original language	English
Pages (from-to)	1-5
Number of pages	5
Journal	Case Reports in Oncology
Volume	11
Issue number	1
DOIs	https://doi.org/10.1159/000485612
Publication status	Published - 2018 Jan 19

Keywords

Imiquimod
Ipilimumab
Nivolumab-resistant melanoma

ASJC Scopus subject areas

Oncology

Access to Document

10.1159/000485612

Cite this

@article{2249fde4df4440c7bd5261e03d7daad7,

title = "Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod",

abstract = "Simultaneous or sequential, planned administration of ipilimumab could significantly enhance the antitumor effects of nivolumab in advanced melanoma patients. On the other hand, the efficacy of ipilimumab for nivolumab-resistant advanced melanoma is extremely poor. Therefore, additional supportive therapy for anti-PD-1 antibody therapy-resistant advanced melanoma has been widely investigated. In this report, we describe a case of multiple in-transit melanomas developing in a nivolumab-resistant patient successfully treated with ipilimumab in combination with imiquimod. Our present case suggested a possible therapy for nivolumab-resistant multiple in-transit melanomas using ipilimumab in combination with topical imiquimod.",

keywords = "Imiquimod, Ipilimumab, Nivolumab-resistant melanoma",

author = "Taku Fujimura and Yumi Kambayashi and Yota Sato and Kayo Tanita and Sadanori Furudate and Akira Tsukada and Hisayuki Tono and Akira Hashimoto and Setsuya Aiba",

note = "Publisher Copyright: {\textcopyright} 2018 The Author(s) Published by S. Karger AG, Basel.",

year = "2018",

month = jan,

day = "19",

doi = "10.1159/000485612",

language = "English",

volume = "11",

pages = "1--5",

journal = "Case Reports in Oncology",

issn = "1662-6575",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

AU - Fujimura, Taku

AU - Kambayashi, Yumi

AU - Sato, Yota

AU - Tanita, Kayo

AU - Furudate, Sadanori

AU - Tsukada, Akira

AU - Tono, Hisayuki

AU - Hashimoto, Akira

AU - Aiba, Setsuya

PY - 2018/1/19

Y1 - 2018/1/19

N2 - Simultaneous or sequential, planned administration of ipilimumab could significantly enhance the antitumor effects of nivolumab in advanced melanoma patients. On the other hand, the efficacy of ipilimumab for nivolumab-resistant advanced melanoma is extremely poor. Therefore, additional supportive therapy for anti-PD-1 antibody therapy-resistant advanced melanoma has been widely investigated. In this report, we describe a case of multiple in-transit melanomas developing in a nivolumab-resistant patient successfully treated with ipilimumab in combination with imiquimod. Our present case suggested a possible therapy for nivolumab-resistant multiple in-transit melanomas using ipilimumab in combination with topical imiquimod.

AB - Simultaneous or sequential, planned administration of ipilimumab could significantly enhance the antitumor effects of nivolumab in advanced melanoma patients. On the other hand, the efficacy of ipilimumab for nivolumab-resistant advanced melanoma is extremely poor. Therefore, additional supportive therapy for anti-PD-1 antibody therapy-resistant advanced melanoma has been widely investigated. In this report, we describe a case of multiple in-transit melanomas developing in a nivolumab-resistant patient successfully treated with ipilimumab in combination with imiquimod. Our present case suggested a possible therapy for nivolumab-resistant multiple in-transit melanomas using ipilimumab in combination with topical imiquimod.

KW - Imiquimod

KW - Ipilimumab

KW - Nivolumab-resistant melanoma

UR - http://www.scopus.com/inward/record.url?scp=85040081769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040081769&partnerID=8YFLogxK

U2 - 10.1159/000485612

DO - 10.1159/000485612

M3 - Article

AN - SCOPUS:85040081769

SN - 1662-6575

VL - 11

SP - 1

EP - 5

JO - Case Reports in Oncology

JF - Case Reports in Oncology

IS - 1

ER -

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this